KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Depreciation & Amortization (CF) (2016 - 2025)

Amgen has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $1.1 billion for Q4 2025, down 18.97% from a year ago — trailing twelve months through Dec 2025 was $5.2 billion (down 7.6% YoY), and the annual figure for FY2025 was $5.2 billion, down 7.6%.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.1 billion at Amgen, down from $1.3 billion in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for AMGN hit a ceiling of $1.4 billion in Q2 2024 and a floor of $828.0 million in Q2 2022.
  • Median Depreciation & Amortization (CF) over the past 5 years was $905.5 million (2022), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 56.25% in 2024 and later decreased 18.97% in 2025.
  • Amgen's Depreciation & Amortization (CF) stood at $852.0 million in 2021, then grew by 6.92% to $911.0 million in 2022, then surged by 51.48% to $1.4 billion in 2023, then grew by 1.23% to $1.4 billion in 2024, then fell by 18.97% to $1.1 billion in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $1.1 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.